Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Usability of CT-P17 Auto-injector in RA
NCT04171414Phase 3Completed
- Sponsor
- Celltrion
- Start
- Sep 2019
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in rheumatoid arthritis (RA), sponsored by Celltrion. Primary endpoint: The Usability as Assessed by Patients Rating Using PRE- and POST-Self-Injection Assessment Questionnaire (SIAQ) at Week 4. Started Sep 2019; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04171414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171414.